Bioactive constituents and the molecular mechanism of Curcumae Rhizoma in the treatment of primary dysmenorrhea based on network pharmacology and molecular docking
- PMID: 33866197
- DOI: 10.1016/j.phymed.2021.153558
Bioactive constituents and the molecular mechanism of Curcumae Rhizoma in the treatment of primary dysmenorrhea based on network pharmacology and molecular docking
Abstract
Background: Curcumae Rhizoma (CR) has a clinical efficacy in activating blood circulation to dissipate blood stasis and has been used for the clinical treatment of qi stagnation and blood stasis (QSBS) primary dysmenorrhea for many years. However, its molecular mechanism is unknown.
Objective: The present study aimed to demonstrate the multicomponent, multitarget and multipathway regulatory molecular mechanisms of CR in the treatment of QSBS primary dysmenorrhea.
Methods: Observations of pathological changes in uterine tissues and biochemical assays were used to confirm that a rat model was successfully established and that CR was effective in the treatment of QSBS primary dysmenorrhea. The main active components of CR in rat plasma were identified and screened by ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry (UPLC-Q/TOF-MS). The component-target-disease network and protein-protein interaction (PPI) network of CR were constructed by a network pharmacology approach. Then, we performed Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Molecular docking was adopted to verify the interactions between the core components and targets of CR to confirm the accuracy of the network pharmacology prediction results. Furthermore, we evaluated the bioactive constituents of CR and molecular mechanism of by which CR promote blood circulation and remove blood stasis via platelet tests in vivo and in vitro and Western blot analysis.
Results: The results of HE staining and biochemical assays of PGF2α, TXB2 and Ca2+ showed that CR was effective in the treatment of QSBS primary dysmenorrhea. A total of 36 active components were identified in CR, and 329 common targets were obtained and used to construct the networks. Of these, 14 core components and 10 core targets of CR in the treatment of primary dysmenorrhea were identified. The GO and KEGG enrichment analyses revealed that the common targets were involved in multiple signaling pathways, including the calcium, cAMP, MAPK, and PI3K-Akt signaling pathways, as well as platelet activation, which is closely related to platelet aggregation. The molecular docking results showed that the 14 core components and 10 core targets could bind spontaneously. Two core targets (MAPK1 and CCR5) and 7 core components (Isoprocurcumenol, Curcumadione, Epiprocurcumenol, (+)-Curdione, Neocurdione, Procurcumenol, and 13-Hydroxygermacrone) were closely related to CR in the treatment of primary dysmenorrhea. Furthermore, the in vivo platelet test showed that CR clearly inhibited platelet aggregation. Five core components ((+)-Curdione, Neocurdione, Isoprocurcumenol, Curcumadione and Procurcumenol) obviously inhibited platelet aggregation in vitro. In addition, based on the relationships among the signaling pathways, we confirmed that CR can effectively inhibit the expression of MAPK and PI3K-Akt signaling pathway-related proteins and decrease the protein expression levels of ERK, JNK, MAPK, PI3K, AKT and CCR5, thereby inhibiting platelet aggregation.
Conclusion: This study demonstrated the bioactive constituents and mechanisms of CR in promoting blood circulation and removing blood stasis and its multicomponent, multitarget and multipathway treatment characteristics in primary dysmenorrhea. The results provide theoretical evidence for the development and utilization of CR.
Keywords: Active components; Molecular docking; Network pharmacology; Platelet aggregation; Primary dysmenorrhea; Rhizoma Curcumae (CR).
Copyright © 2021 Elsevier GmbH. All rights reserved.
Similar articles
-
Active ingredients screening and pharmacological mechanism research of curcumae rhizoma-sparganii rhizoma herb pair ameliorates liver fibrosis based on network pharmacology.J Ethnopharmacol. 2023 Apr 6;305:116111. doi: 10.1016/j.jep.2022.116111. Epub 2022 Dec 30. J Ethnopharmacol. 2023. PMID: 36592822
-
[Material basis and mechanism of action of Arisaematis Rhizoma Preparatum in treatment of chronic obstructive pulmonary disease based on animal experiments, UPLC Q-Exactive Orbitrap MS, and network pharmacology].Zhongguo Zhong Yao Za Zhi. 2025 Apr;50(7):1792-1802. doi: 10.19540/j.cnki.cjcmm.20240206.301. Zhongguo Zhong Yao Za Zhi. 2025. PMID: 40350871 Chinese.
-
[Anti-colorectal cancer mechanism of Astragali Radix-Curcumae Rhizoma-Paridis Rhizoma based on network pharmacology and experimental verification].Zhongguo Zhong Yao Za Zhi. 2022 Feb;47(3):776-785. doi: 10.19540/j.cnki.cjcmm.20211103.702. Zhongguo Zhong Yao Za Zhi. 2022. PMID: 35178961 Chinese.
-
Network pharmacology and molecular docking to explore the pharmacological mechanism of Yifei Tongluo granules in treating idiopathic pulmonary fibrosis: A review.Medicine (Baltimore). 2023 Jun 2;102(22):e33729. doi: 10.1097/MD.0000000000033729. Medicine (Baltimore). 2023. PMID: 37266620 Free PMC article. Review.
-
Mechanisms of main components in Curcuma longa L. on hepatic fibrosis based on network pharmacology and molecular docking: A review.Medicine (Baltimore). 2023 Jul 21;102(29):e34353. doi: 10.1097/MD.0000000000034353. Medicine (Baltimore). 2023. PMID: 37478207 Free PMC article. Review.
Cited by
-
Study on the mechanism of Panax notoginseng-Salvia miltiorrhiza herb pair on invigorating blood circulation and eliminating blood stasis by blocking the conversion of arachidonic acid to prostaglandin.J Nat Med. 2024 Mar;78(2):411-426. doi: 10.1007/s11418-023-01773-z. Epub 2024 Jan 23. J Nat Med. 2024. PMID: 38261160
-
The therapeutic mechanism of Curcumae Radix against primary dysmenorrea based on 5-HTR/Ca2+/MAPK and fatty acids metabolomics.Front Pharmacol. 2023 Mar 9;14:1087654. doi: 10.3389/fphar.2023.1087654. eCollection 2023. Front Pharmacol. 2023. PMID: 36969877 Free PMC article.
-
The Controversial Roles of Areca Nut: Medicine or Toxin?Int J Mol Sci. 2023 May 19;24(10):8996. doi: 10.3390/ijms24108996. Int J Mol Sci. 2023. PMID: 37240342 Free PMC article. Review.
-
Agarwood Chromone Alleviates Gastric Ulcers by Inhibiting the NF-κB and Caspase Pathways Based on Network Pharmacology and Molecular Docking.Pharmaceuticals (Basel). 2025 Mar 31;18(4):514. doi: 10.3390/ph18040514. Pharmaceuticals (Basel). 2025. PMID: 40283949 Free PMC article.
-
Research Progress on Sesquiterpenoids of Curcumae Rhizoma and Their Pharmacological Effects.Biomolecules. 2024 Mar 23;14(4):387. doi: 10.3390/biom14040387. Biomolecules. 2024. PMID: 38672405 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
